Incyte Corp (INCY): Shareholders' Equity
$5.17B
As of 2025-12-31
$5.62B
As of 2026-03-31
+5.7%
3-year compound annual growth
+14.6%
5-year compound annual growth
+40.6%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.17B | +49.9% | 2026-02-10, Balance as of period end |
| 2024-12-31 | $3.45B | -33.6% | 2026-02-10, Balance as of period end |
| 2023-12-31 | $5.19B | +18.8% | 2026-02-10, Balance as of period end |
| 2022-12-31 | $4.37B | +15.9% | 2025-02-10, Balance as of period end |
| 2021-12-31 | $3.77B | +44.4% | 2024-02-13, Balance as of period end |
| 2020-12-31 | $2.61B | +0.5% | 2023-02-07, Balance as of period end |
| 2019-12-31 | $2.60B | +34.9% | 2022-02-08, Balance as of period end |
| 2018-12-31 | $1.93B | +18.1% | 2021-02-09, Balance as of period end |
| 2017-12-31 | $1.63B | +288.7% | 2020-02-13, Balance as of period end |
| 2016-12-31 | $419.47M | +145.1% | 2019-02-14, Balance as of period end |
| 2015-12-31 | $171.16M | n/m | 2018-02-15, Balance as of period end |
| 2014-12-31 | -$81.63M | n/m | 2017-02-14, Balance as of period end |
| 2013-12-31 | -$193.11M | n/m | 2016-02-12, Balance as of period end |
| 2012-12-31 | -$174.96M | n/m | 2015-02-17, Balance as of period end |
| 2011-12-31 | -$227.08M | n/m | 2014-02-21, Balance as of period end |
| 2010-12-31 | -$88.64M | n/m | 2013-02-21, Balance as of period end |
| 2009-12-31 | -$102.38M | n/a | 2012-02-22, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Incyte Corp (INCY) | 2025-12-31 | $5.17B | +49.9% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.17B | -8.6% |
| Icon PLC (ICLR) | 2025-12-31 | $9.19B | -2.6% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $459.07M | -44.4% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $6.63B | +9.3% |
| NRC Health (NRC) | 2025-12-31 | $13.99M | -55.3% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $171.49M | -16.9% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $267.03M | -7.2% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $11.14M | +109.3% |
Compare INCY, CRL, ICLR, MEDP side by side · Screen every company in Services-Commercial Physical & Biological Research ↗